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Deficiency In Hypertransfused Patients with Thalassemia Major 
by 
Peter Alexander Merkel 
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Diabetes mellitus in patients receiving 
hypertransfusion therapy for thalassemia major is usually 
attributed to damage to (3 cells. To examine whether iron 
overload might lead to insulin resistance even before the 
development of impaired insulin secretion, 12 children with 
thalassemia major (4 prepubertal, 8 pubertal) with normal or 
only modestly impaired glucose tolerance on chelation 
therapy were studied. Each patient received intravenous 
insulin (40 mU/m2-min) to raise plasma insulin to s;80 jzU/ml 
for 2 hours while plasma glucose was maintained at 90 ± 5 
mg/dl by a variable rate glucose infusion (euglycemic 
insulin clamp technique). Under these conditions of 
euglycemia and hyperinsulinemia, the glucose infusion rate 
reflects total body glucose metabolism (M) and is an index 
of insulin sensitivity. In prepubertal patients with 
l 

thalassemia major, M values (319 ± 23 mg/m2 min) were 
similar to those in prepubertal normal controls (315 ± 41 
mg/m2-min, P=not significant). In contrast, insulin 
sensitivity was markedly reduced in pubertal thalassemics 
(151 ± 17 vs. 224 ± 15 mg/m2-min in normal pubertal 
controls, p<0.01). The reduction in insulin sensitivity in 
patients with thalassemia major was correlated with iron 
load (r= -0.77, p<0.01). 
The pubertal, but not the prepubertal thalassemics, had 
an excessive rise in plasma insulin levels after oral 
glucose (p<0.001). Furthermore, in response to a standard 
125 mg/dl (6.9 mmol/1) hyperglycemic stimulus (hyperglycemic 
clamp technique), 2-3 fold greater than normal early and 
late insulin and C-peptide responses were demonstrated in 
the pubertal patients. 
These data suggest that insulin sensitivity is reduced 
in children with thalassemia major when they reach puberty 
due, in part, to chronic iron overload. Compensatory 
increases in insulin secretion may help maintain normal 
glucose tolerance in the face of insulin resistance at this 
stage of the disease. Increased insulin secretion due to 
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HISTORY OF THALASSEMIA 
In 1925, Drs. Thomas B. Cooley and Pearl Lee first 
reported five cases of children with "... anemia, 
splenomegaly, and some enlargement of the liver...." They 
further described a "peculiar" appearance of some of the 
children "... caused by enlargement of the cranial and 
facial bones, combined with the skin discoloration."1 
Cooley et. al. realized that while some of the cases were 
similar to those of von Jaksch's anemia or a leukemia, this 
new entity deserved separate classification.2 They 
suggested that the disease was "... a form of hemolytic 
anemia, developing in early life and dependent probably on 
some congenital defect in the hemolytopoietic system."2 
These early observations and theories proved to be 
surprisingly accurate and the new syndrome came to be known 
as Cooley's anemia. This eponym remains in use today but 
has been largely supplanted by the term "thalassemia" which 
was first coined by Whipple and Bradford in 1932.2'4 The 
term is based on the Greek words "thalassa" meaning "the 




authors' observations that most cases occurred in people of 
Mediterranean descent. In the more than sixty years since 
Cooley's first description of thalassemia, enormous strides 
have been made in our understanding of its molecular basis 
and pathophysiology leading to advances in the diagnosis and 
treatment of this disease. 
MOLECULAR BASIS OF THE THALASSEMIAS 
The term thalassemia is used to describe a heterogenous 
group of inherited anemias characterized by decreased or 
absent production of one or more of the polypeptide chains 
which make up human hemoglobin. Most thalassemias involve 
the polypeptide chains of hemoglobin A1 (a2/32). Thalassemia 
genes are inherited in an autosomal dominant pattern. When 
the synthesis of the a-globin molecule is impaired or 
absent, the resulting diseases are referred to as the a- 
thalassemias. Similarly, when synthesis of the /3-globin 
molecule is reduced, the resulting syndromes are known as 
the /3-thalassemias. Other, rarer, forms of thalassemia 
exist which correspond to defects in production of various 
non-alpha or non-beta hemoglobin chains.5 
In /3-thalassemia, normal /3-globin genes are present but 
are not expressed due to the action of the thalassemia gene 
complex that alters /3-globin gene expression. Although the 
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basic failure of /3-globin chain synthesis most often results 
from problems in mRNA template processing, /3-thalassemia can 
be caused by any of a variety of genetic mutations causing 
disturbances at different steps of globin gene expression 
and more than 30 different mutations have been described.5 
The a-thalassemias are caused by similar problems at one or 
both of the a-globin loci. Most children with four a-loci 
mutations die in utero (fetal hydrops syndrome). Patients 
with three a-loci mutations have hemoglobin H disease that 
is clinically similar to thalassemia intermedia. Patients 
with two or one a-loci mutations are asymptomatic carriers. 
Because this investigation concerns /3-thalassemia patients 
only, further discussion of the a-thalassemias is beyond the 
scope of this paper. 
/3-THALASSEMIAS 
Geographic Distribution of /3-Thalassemia 
The distribution of the gene for /3-thalassemia is 
centered in the countries bordering the Mediterranean Sea. 
Especially high frequencies occur in Italy (up to 5%) and 
Greece (5-15%) and children from Italian or Greek American 
families comprise by far the majority of patients in this 
country.5 Thalassemia is also found in the Middle East, 
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Africa and Southern Asia. The gene frequency in black 
Americans is approximately 0.8%.6 It is believed that the 
recent rise in immigration of people of Southeast Asian 
decent will lead to a sharp increase in the number of new 
cases of thalassemia major in the United States in the 
coming decade.7'8 
The /3-thalassemias are usually classified as "minor," 
"major" and "intermedia" forms based on both genotype and 
clinical presentation. 
Thalassemia Minor 
Individuals with thalassemia minor or thalassemia trait 
are heterozygous for the thalassemia gene and /3-globin is 
synthesized at approximately half the rate of normal, 
resulting in a mild form of microcytic hypochromic anemia. 
Laboratory studies reveal reduced mean corpuscular volume, 
decreased mean corpuscular hemoglobin, decreased hemoglobin 
(decreased 1.0-2.0 g/dl verses age and sex matched controls) 
and decreased osmotic fragility.9 Red blood cell count and 
reticulocyte counts are normal or somewhat elevated. 
Peripheral blood smears show some hypochromia, target cells, 
poikilocytes, ovalocytes, and basophilic stippling. The 
diagnosis can be made by quantitative hemoglobin 
electrophoresis showing elevated hemoglobin A2 levels 
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(>3.5%). Although most people with thalassemia minor are 
asymptomatic, some patients complain of easy fatiguability 
and the anemia may be worsened by pregnancy or iron 
deficient states.5 Making a diagnosis of thalassemia trait 
is useful in explaining abnormal hematological laboratory 
findings and in excluding iron deficiency anemia with its 
need for further diagnostic studies and therapy. 
Establishment of a diagnosis is the rationale for screening 
ethnic groups and individuals at high risk for carrying the 
gene in order to provide them with genetic counseling. 
Thalassemia Major 
In contrast to the relatively benign course of 
thalassemia minor, the homozygous state for /3-thalassemia 
leads to a severe chronic hemolytic anemia known as 
thalassemia major. The anemia is so severe that early death 
occurs unless regular blood transfusion is initiated. The 
near absence of /3-globin production in these patients leads 
to low or absent levels of hemoglobin A^. Although there is 
an increase in gamma and delta-chain synthesis, the response 
does not compensate for the loss of beta-chain production. 
Since the rate of a-globin production remains normal, the 
total number of a-chains greatly outnumber non-a chains. 
These "unbalanced" a-chains aggregate within red blood cells 
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into unstable inclusions, or "Fessas bodies."5'10'11 These 
inclusion bodies cause death of early red blood cells in the 
bone marrow and markedly shortened survival of those that 
reach the circulation. Along with the total decrease in 
hemoglobin content, this process results in production of 
hypochromic, microcytic and poikilocytic red blood cells. 
Thalassemia Intermedia 
Approximately 10% of patients with homozygous (3- 
thalassemia have clinical disease with degrees of anemia and 
symptoms that are less severe or delayed than those 
described below. This syndrome is known as thalassemia 
intermedia. These patients vary greatly in their clinical 
course. They may require only minimal transfusion support 
early in the disease, but splenectomy and full transfusion 
therapy may eventually be needed.5 
CLINICAL FINDINGS IN UNTREATED THALASSEMIA MAJOR 
The clinical manifestations of untreated thalassemia 
major are a direct result of hemolytic anemia and become 
apparent after the infant is six months old, when fetal 
hemoglobin synthesis normally diminishes. Presenting 
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clinical features can include pallor, jaundice, 
irritability, growth retardation, and abdominal swelling due 
to liver and spleen enlargement.5 Cardiac dilation due to 
the severe anemia may be observed. Compensatory marrow 
hypertrophy occurs causing the dramatic skeletal changes of 
thalassemia which Cooley first described: frontal bossing, 
maxillary enlargement with dental abnormalities, severe 
osteoporosis and early epiphyseal fusion.2'5 The liver, 
kidneys and spleen all suffer enlargement due to 
extramedullary hematopoiesis. Splenomegaly also results 
from the organ's role in red blood cell removal. Without 
transfusion therapy, the life expectancy of patients 
averages less than four years. 
Laboratory findings in untreated thalassemia major are 
those of a severe uncomplicated hemolytic anemia. After 
about six months of age the hemoglobin level falls as low as 
3.0-4.0 g/dl. Peripheral blood smear reveals the classic 
hypochromic, microcytic cells with poikilocytes, target 
cells as well as cells with the Fessa bodies described 
above. The reticulocyte count is between 2-8%. The red 
blood cells are resistant to hemolysis, a finding Cooley 
first noted and one that helps distinguish the disease from 
other forms of hereditary hemolytic anemia such as 
congenital spherocytosis.2 The bilirubin is elevated to 
levels of 2.0-4.0 mg/dl. Hemoglobin F is the predominant 
hemoglobin fraction (20-60%), yet the total hemoglobin level 

8 
is still very low. The ratio of hemoglobin A2‘^i is 
increased from the normal 1:30 to less than 1:20.5 
THERAPY FOR THALASSEMIA MAJOR 
Prevention: Genetic Counseling 
The best treatment for thalassemia major is, of course, 
prevention. This can only be attained by preventing the 
births of infants homozygous for thalassemia. To achieve 
this goal, large-scale programs for genetic screening, 
prenatal diagnosis and genetic counseling have been 
established for populations at high risk for carrying the 
thalassemia gene. Screening for thalassemia trait can be 
accomplished by measuring mean corpuscular volume and 
follow-up quantitative hemoglobin A2 determination in 
patients with microcytosis.9'12 Prenatal diagnosis of 
thalassemia major can be made by fetal blood sampling and 
globin chain incorporation studies13'14 or by DNA 
polymorphisms in cells recovered by amniocentesis15 or 
chorionic villus biopsy.16'17 Decisions by at-risk families 
not to have children as well as therapeutic abortions by 
women carrying affected fetuses are options some families 
involved in the screening programs have taken. 
Implementation of comprehensive education and screening 
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programs for high-risk populations in the 1970's resulted in 
a significant decrease in the number of new cases of 
^-thalassemia major through the early 1980's and has been 
spectacularly successful in Cyprus where more than 90% of 
the births of affected fetuses have been prevented.8'18 
Continued effort in such preventive measures must be 
maintained and modified to account for any population shifts 
of at-risk groups. 
Hvootransfusion Therapy 
The untreated patient with thalassemia major has a very 
short life expectancy. It was recognized early that 
transfusions were necessary to sustain the life of these 
patients. Because of concern over the development of iron 
overload, transfusions were given sparingly. Therefore, the 
childrens' hemoglobin was sometimes 5.0-6.0 g/dl or lower 
and they were often symptomatic. The cardiomegaly, 
erythroid hyperplasia and severe skeletal deformities that 
occur in untreated patients were still present in the 
minimally transfused patients. Furthermore, even with this 
transfusion schedule, a tremendous iron burden developed 
over the years causing multiple organ disturbances including 
cardiac failure, growth and endocrine abnormalities and 
liver dysfunction. The life expectancy of patients with 
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thalassemia major on this transfusion schedule averaged 
15-20 years.5 
Hypertransfusion Therapy 
The approach to treating patients with thalassemia 
major changed dramatically in 1964 when Wolman published the 
results of a retrospective cross-sectional survey of 
thalassemic patients comparing their average hemoglobin 
levels with their clinical conditions during transfusion 
therapy.19 He showed that compared to patients whose 
hemoglobin levels were maintained between 4.0-5.9 g/dl, 
those patients with hemoglobin levels maintained between 
8.0-9.9 g/dl had significantly better short-term clinical 
outcomes. Patients with higher hemoglobin levels displayed 
less growth retardation, fewer skeletal abnormalities, 
including facial disfigurement, less degrees of 
hepatosplenomegaly and less severe cardiomegaly. After this 
report, many centers began using transfusion regimens that 
kept hemoglobin levels above 10.0 g/dl. This protocol came 
to be known as "hypertransfusion" therapy. Numerous studies 
have demonstrated the distinct advantages of 
hypertransfusion therapy: normalization of growth, 
suppression of erythropoiesis, decrease in liver, spleen, 
and cardiac enlargement. Most importantly, by eliminating 
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the anemia and marrow hyperplasia, this regimen allows 
patients to lead full, active lives without the physical 
disfigurement previously seen.5 
Hypertransfusion therapy has become the standard 
regimen for treating patients with thalassemia major in the 
United States and other countries economically capable of 
its implementation. One center's recent recommendations for 
a "supertransfusion" protocol is the maintenance of baseline 
hemoglobin levels above 11.5 g/dl, a level felt to be a 
compromise between the goal of maintaining a normal 
hemoglobin (>14.0 g/dl) and the increased transfusion 
requirement that would be required to achieve such a level. 
Such hemoglobin levels can be achieved by transfusions of 
10 ml/kg of filtered washed packed red blood cells given 
every three weeks.20 The Yale-New Haven Hospital 
Thalassemia Clinic maintains hemoglobin above 10.0 g/dl by 
transfusion of 15 ml/kg of washed packed red blood cells 
every 4-5 weeks. 
Although the greater number of transfusions leads to an 
increase in the amount of iron received by the patient, this 
may be offset somewhat by a decrease in intestinal iron 
absorption due to correction of anemia.19 Nevertheless, 
iron overload remains the major cause of morbidity and 
mortality in thalassemic patients. Thus, adjuvant forms of 
therapy are designed to increase red blood cell survival and 




Before the adoption of transfusion therapy, patients 
with thalassemia major often required early splenectomy due 
to massive splenomegaly which caused mechanical symptoms, 
thrombocytopenia and neutropenia.5 With current 
hypertransfusion regimens, massive splenomegaly does not 
occur, although some organ enlargement is inevitable.20 
However, splenectomy is still indicated when there is 
evidence of a shortened survival time of transfused red 
blood cells. After splenectomy, transfusion requirements 
decrease and, therefore, the patient's acquired iron burden 
is reduced. The operation is usually performed when the 
patient is at least six years old to allow for the 
development of humoral immunity to bacteria, especially 
encapsulated organisms, such as Streptococcus pneumoniae and 
Haemophilus influenzae.5•20 
Experimental and Future Therapies 
In 1980 Propper et. al. reported on the use of 
neocytes, red blood cells with a mean age of 20-30 days 
compared with the mean age of 60 days for regularly 
transfused red blood cells. Such neocytes are harvested 
from donors using a continuing flow cell separator similar 
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to that used to collect white blood cells.21 It was shown 
that transfused neocytes have prolonged in vivo survival 
compared to traditionally transfused red blood cells. Other 
studies, however, have not shown significantly decreased 
blood requirements with neocytes (Bove JR and Pearson HA, 
1988, personal communication). Furthermore, this therapy 
involves extreme cost and exposure of patients to an 
increased number of blood donors. These uncertainties have 
rendered neocyte therapy still experimental.20 
Bone marrow transplantation is theoretically a cure for 
thalassemia major but has carried significant risks. The 
first successful bone marrow transplant of a patient with 
thalassemia major was accomplished in 1982.22 This was 
followed by a number of trials in both infants and older 
children. A recent series by Lucarelli et. al. in 40 
patients 10-18 years of age reported a 70% success rate but 
a 25% mortality rate.23 The therapy currently requires 
histocompatible sibling marrow donors. While a potentially 
promising therapy, bone marrow transplantation for 
thalassemia major remains experimental and awaits further 
progress in risk-reduction. The increased use of the 
procedure for genetic and oncologic indications should 
continue to help improve the technique's effectiveness and 
safety. 
The modification of marrow erythroid differentiation 
through the use of chemotherapeutic agents such as 5- 
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azacytidine and hydroxyurea is another experimental approach 
being considered for patients with thalassemia major.24-26 
IRON OVERLOAD IN HYPERTRANSFUSED PATIENTS WITH THALASSEMIA 
MAJOR 
Iron Balance 
The normal homeostasis of iron, a crucial element for 
hemoglobin synthesis as well as many other intracellular 
mechanisms, is maintained through complex interactions of 
plasma proteins, the reticulo-endothelial system and tissue 
and red blood cell stores. Dietary iron is absorbed in the 
upper small intestine. In the circulation iron combines 
with apotransferrin to form transferrin, a ^-globulin 
molecule that acts as a carrier for iron in the plasma. 
Approximately 70% of the body's iron pool is normally 
present in heme compounds (hemoglobin and myoglobin). 
Another 15-30% is stored in the liver as ferritin, formed 
when iron combines with apoferritin, and a smaller amount of 
iron is present as hemosiderin, made up of large aggregates 
of ferritin. When senescent red blood cells are destroyed 
within the reticulo-endothelial system, the free iron is 
transported by transferrin for use in either new hemoglobin 
synthesis or storage in tissues.27 
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The human body has flexibility in its capacity to 
maintain iron balance by self-regulating iron absorption. 
If tissue iron accumulates due to increased oral intake, the 
storage capacities of apoferritin and transferrin, both 
usually only partly utilized, become saturated and the rate 
of gastro-intestinal iron absorption decreases sharply. 
Mucosal iron deposition itself can interfere with iron 
absorption. On the other hand, total body iron deficiency 
causes increased binding capacity of transferrin and 
decreased iron storage pools resulting in increased gastro¬ 
intestinal absorption.27 However, the body's ability to 
excrete iron is severely limited. 
Transfusions are not the only sources of iron in 
thalassemic patients. During the hypotransfusion era, 
thalassemic patients were calculated to have hemosiderosis 
and total body iron burdens that exceeded the amount of iron 
known to have been acquired through transfusions. It was 
postulated that increased gastro-intestinal iron absorption 
accounted for this difference.28 Early work with iron 
tracer studies demonstrated that patients with 
hemoglobinopathies and other forms of refractory anemias 
absorb dietary iron far in excess of normal non-anemic 
individuals.29 Erlandson et. al. in 1962 demonstrated that 
patients with thalassemia major had an increase in 
intestinal iron absorption compared to normal children when 
the patients' hemoglobin levels were 6.0-8.5 g/dl but had 
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normal intestinal iron absorption when their hemoglobin 
levels were maintained at 9.5-12.6 g/dl.30 Furthermore, 
this study found no increased rate of intestinal iron 
absorption in patients with thalassemia trait. They 
proposed that the increased iron absorption is somehow 
related to the increased ineffective erythropoiesis seen 
when patients' hemoglobin levels are low. Iron absorption 
decreases markedly when hemoglobin levels are restored to 
normal. Thus, the increased iron administered during 
hypertransfusion therapy may be offset somewhat by decreased 
gastro-intestinal iron absorption due to prevention of 
severe anemia. 
Patients with thalassemia major receive approximately 
5-15 mg of transfused iron per day (based on 200 mg of iron 
per 250 ml of packed red blood cells) and will be treated 
with hundreds of units of blood in their lifetime.31'32 
These patients are incapable of excreting significant 
amounts of this excess iron and, if left untreated, 
inevitably develop severe hemosiderosis. By 11 years of 
age, the average hypertransfused patient has received 
approximately 28 grams of iron with 1-2 grams being the 
body's normal iron stores.32 Increasing age and, therefore, 




Clinical and Pathological Complications 
The adoption of hypertransfusion therapy has greatly 
improved the quality and duration of life for patients with 
thalassemia major. However, a complication of this therapy, 
transfusional hemosiderosis, is now the major cause of 
morbidity and mortality in these patients. 
Iron overload was first discussed by Whipple and 
Bradford in 1936.3 Studies have demonstrated iron 
deposition in multiple organs with pathological findings 
similar to those seen in idiopathic hemochromatosis.28'33 
Schafer et. al. also found similar clinical manifestations 
of cardiac, endocrine and hepatic damage in non-thalassemic 
adult patients given intensive short-term transfusion 
support.34 The most common pathologic and clinical findings 
of acquired iron overload are described below. 
Cardiac Complications 
Cardiac damage and arrhythmias have long been 
recognized as the most severe complications of acquired 
hemochromatosis in thalassemic patients and remain today the 
chief cause of death in most patients. In 1964 Engle 
reported on the cardiac status of a series of patients with 
thalassemia major or thalassemia intermedia who had been 
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receiving traditional hypotransfusion therapy.35 In that 
series, 80% of the patients had cardiac involvement 
including pericarditis, atrial and ventricular arrhythmias 
and congestive heart failure. She noted that the cardiac 
complications generally became evident in the second decade 
of life. Congestive heart failure resulted in the death of 
23 of 24 patients with this diagnosis. Engle ascribed these 
clinical events to hemochromatosis which was pronounced in 
all patients autopsied. Ehlers et. al. in 1980 reported on 
a second group of patients at the same institution finding 
very similar results.36 The patients in this study who died 
from congestive heart failure were 9-33 years old with a 
mean age at death of 18. The patients in both of the above 
studies were not treated with iron chelation therapy. In 
1979 Leon et. al. studied a group of transfusion dependent 
anemia patients with radionuclide cineangiography and 
demonstrated a significant decrease in ejection fraction in 
the transfused patients compared to normal controls.37 
Furthermore, the magnitude of left ventricular dysfunction 
was inversely correlated with the number of transfusions. 
Similar results were found in patients with thalassemia 
major studied by Freeman et. al. in 1983.38 The results of 




In 1954, Ellis demonstrated liver fibrosis and 
siderosis at autopsy in 11 of 13 patients treated 
conventionally for thalassemia major.28 He described 
pathological changes very similar to those seen in 
idiopathic hemochromatosis. Other studies reported similar 
pathological findings in thalassemia major33 and 
transfusion-acquired iron overload.34 Liver function tests 
in patients with thalassemia major sometimes reveal hyper- 
or hypogammaglobulinemia, moderate decreases in coagulation 
factor levels, and elevated transaminase levels.5'34 Some 
of these changes may be secondary to transfusion-acquired 
viral hepatitis which may lead to chronic liver disease in 
thalassemic patients.39 Iron deposition can be carcinogenic 
and one case of hepatocellular carcinoma has been reported 
in a patient with thalassemia major.40 Infection with 
hepatitis B virus may further predispose patients to liver 
malignancy. As patients with thalassemia survive longer, 
liver malignancies may become more common and careful 




Multiple endocrinopathies have been associated with 
thalassemia major and the role of iron overload in these 
findings is not always clear. Before the adoption of 
hypertransfusion therapy, patients with thalassemia major 
were regularly found to have growth retardation thought 
secondary to their anemia.5 Hypertransfusion protocols have 
resulted in improved growth. However, in a study of 250 
patients with thalassemia major begun on chelation therapy, 
37% showed growth that was 2 standard deviations below age- 
and sex-matched controls.41 It must be noted that many of 
the patients in this study were not begun on deferoxamine 
therapy until later in life. Therefore, the results on 
growth of early aggressive chelation is not yet known. The 
delay or absence of sexual maturation in patients with 
thalassemia major is very common and is felt to be due to 
hemosiderotic damage of the hypothalamus.42-45 
Iron deposition has been demonstrated in virtually all 
endocrine glands studied including thyroid, parathyroid, 
adrenal, testes and pancreas.22'42'44'45 Furthermore, 
studies have found deficiencies in pituitary, parathyroid, 
adrenal, testicular and pancreatic function.42'44-49 
Problems with sexual maturation are believed to be secondary 
to hypothalamic-pituitary dysfunction and/or possible 
gonadal hormonal insensitivity resulting in the 
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hypogonadotropic hypogonadism seen in thalassemia 
major.44'45'50 Hypoparathyroidism has been reported in 
patients with thalassemia major and demonstrated by 
provocative stimulation tests.44'48'51'52 The 
hypoparathyroidism seen in thalassemia major is felt 
secondary to acquired iron overload. Some authors have 
reported elevated thyroid stimulating hormone levels in 
patients with thalassemia major.47'48 However, most studies 
indicate that despite iron deposition in the thyroid gland 
and some thyroid function test abnormalities, patients with 
thalassemia major are generally euthyroid.42'42'47'48'52'54 
Iron Chelation Therapy: Deferoxamine 
Without an effective means of removing excess body iron 
stores, hypertransfused patients with thalassemia major 
rapidly develop severe hemosiderosis with its accompanying 
cardiac and endocrinologic complications. Phlebotomy 
therapy, while effective in some iron overloaded conditions, 
is clearly out of the question in such transfusion-dependent 
anemic patients. Therefore, an iron chelating pharmacologic 
agent was long sought after. Various agents were 
investigated including penicillamine, EDTA, and tricalcium 




In I960, deferoxamine (also referred to as 
desferrioxamine), a sideraphore obtained from Streptomyces 
pilosus was demonstrated to be a highly specific iron 
chelator.5'55 Oral deferoxamine is not well absorbed. The 
medication was initially given by intramuscular injection, a 
route of administration that proved to be very painful. 
Studies in the late 1970's demonstrated that deferoxamine- 
induced iron excretion could be greatly increased by slow, 
continuous intravenous administration.5'56 Subsequently, 
Graziano et. al. demonstrated that continuous subcutaneous 
administration of deferoxamine was nearly (79%) as effective 
as the intravenous route of administration.57 Subcutaneous 
administration can now be accomplished at home through the 
use of portable infusion pumps and this is now the method of 
choice for deferoxamine therapy. Some treatment protocols 
combine intravenous deferoxamine administration during 
transfusions with up to 7 days per week subcutaneous 
infusion schedules. 
In 1968 Wapnick et. al. reported that ascorbic acid 
deficiency was frequently seen in people with iron 
overload.58 Further investigation demonstrated that oral 
doses of ascorbic acid repleted body stores and 
significantly increased deferoxamine-induced urinary iron 
excretion in subjects with transfusion acquired 
hemosiderosis.59 Subsequent studies have confirmed these 
results and ascorbic acid replacement therapy in moderate 

23 
(100 mg/day), non-cardiotoxic doses is now a regular 
component of iron-chelation therapy.5 
Hypertransfused patients with thalassemia major treated 
with a regimen of chronic, slow subcutaneous deferoxamine 
and ascorbic acid repletion have been able to excrete up to 
100 mg of iron in urine per day.5 This response may 
diminish over time despite the fact that serum ferritin 
levels and calculated iron burden remain increased in these 
patients.20,60,61 
Deferoxamine therapy is generally well tolerated but 
the potential toxicity of chronic use is a concern. Some 
patients suffer irritation at the infusion sites but 
infection, tachyphylaxis or hypersensitivity are only rarely 
seen.5 Sensorineural hearing loss, retinal toxicity, visual 
impairment and possible cataract formation have been 
reported with high dose deferoxamine therapy.62-64 These 
impairments were reversible in only a few of the patients 
with discontinuation of deferoxamine. Regular auditory and 
ophthalmologic exams have been suggested for all patients 
receiving deferoxamine. 
Compliance with using the subcutaneous infusion 
protocol has also proven to be a problem, especially among 
adolescent patients.5'20'65'66 Despite the inconvenience, 
the great expense and the possible toxicity of therapy, 
deferoxamine is the only known effective iron chelation 
agent available and will remain the mainstay of therapy in 

hypertransfused patients with thalassemia major until a 
better agent is available. 
Effectiveness of Deferoxamine 
Since its introduction, investigators have studied 
deferoxamine's ability to affect the clinical course of 
patients with thalassemia major. In 1974 Barry et. al. 
reported the results of a randomized prospective trial of 
intramuscular deferoxamine chelation therapy in 18 
hypertransfused patients with thalassemia major followed 
with serial liver biopsies.60 After five years, non- 
chelated control patients had increased liver iron 
concentrations compared to the chelation-treated patients 
who showed minimal changes in liver iron stores. 
Furthermore, hepatic fibrosis increased in the control group 
but remained stable in the chelated patients. The two 
groups showed no significant differences in clinical 
progression. However, pubertal development was delayed in 4 
of 5 untreated patients but in only 1 of 4 chelated 
patients. It is likely that clinical differences were not 
seen because the study only covered five years and the 
patients were not yet in their twenties, when the more 
severe complications of the hemosiderosis become apparent. 
In a small uncontrolled trial, Cohen et. al. demonstrated 
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that liver iron stores could be depleted and the progression 
of liver fibrosis stopped through even more intensive 
deferoxamine therapy.67 
Because chronic subcutaneous deferoxamine therapy is 
relatively new, no large series of patients have been 
followed from infancy to their twenties to examine the 
clinical benefits of maximum chelation therapy. 
Nevertheless, some studies have shown improved cardiac 
function or at least delayed onset of ventricular failure 
with chelation therapy.38'66'68-72 Kaye and Owen in 1978 
reported on 28 patients with thalassemia major ages 7-23 
years.68 They found that of 11 patients considered 
inadequately chelated, 7 developed "major" cardiac 
arrhythmias while none of the 17 "well-chelated" patients 
developed arrhythmias. Freeman et. al. in 1983 demonstrated 
that early subclinical left ventricular dysfunction 
correlated with increased iron burden and could be reversed 
in some patients after intensive chelation therapy.38 In 
1985 Wolfe et. al. examined cardiac status in patients with 
thalassemia major started on iron-chelation therapy after 
age 10.69 They found that while 12 of 19 "non-compliant" 
patients were affected by cardiac disease, only 1 of 17 
compliant patients was. Giardina et. al. in 1985 reported 
on patients with thalassemia major begun on iron-chelation 
therapy and followed for five years.70 Their results, while 
only short term and preliminary, indicated that improved 
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cardiac health could be attained and progressive myocardial 
dysfunction delayed with chelation therapy. The best 
results were seen in the patients who had yet to reach their 
twenties, the age of greatest cardiac risk. Grisaru et. al. 
in 1986 reported improved left ventricular function in 20 
patients compliant with chelation therapy and deterioration 
of ventricular function in 15 non-compliant patients.71 A 
study of the population involved in the current 
investigation also revealed preliminary findings of reduced 
cardiac damage in patients compliant with chelation 
therapy.66 
If cardiac disease, the leading cause of death in 
thalassemia major, could be prevented with chelation 
therapy, then life expectancy should rise. Modell et. al. 
in 1982 reported the first evidence that aggressive 
deferoxamine therapy results in increased life expectancy 
compared to untreated patients.73 However, their 
conclusions were based on data collected from a group of 
patients 20 years of age or younger. While future 
randomized trials of treated verses untreated patients would 
be unethical, continued follow-up of patients treated since 
infancy will allow for more definitive conclusions. There 
is reason to be optimistic that deferoxamine therapy, if 
started at an early age, will markedly improve the outcome 
of patients with thalassemia major. 

27 
CARBOHYDRATE TOLERANCE IN THALASSEMIA MAJOR 
Pancreatic Iron Deposition 
Most autopsy studies of patients with thalassemia major 
reveal severe hemosiderotic pancreatic involvement. Diffuse 
pancreatic fibrosis and iron deposition in both acinar and 
islet cells have been described.28'33 Both of these studies 
compare the pancreatic findings in thalassemia major to 
idiopathic hemochromatosis. 
Previous Studies of Diabetes Mellitus in Thalassemia Major 
Diabetes mellitus is a well known complication of 
thalassemia major that generally affects patients beyond 
their teenage years. However, the pathophysiology of these 
patients' carbohydrate intolerance is not totally clear. 
Diabetes mellitus in thalassemia has usually been attributed 
to insulin deficiency from the toxic effects of iron 
deposited in pancreatic islets.28'33'46'47'74-79 An 
experimental model of acquired hemochromatosis was developed 
in 1979 by Awai et. al..77 These investigators reported 
that rats treated with a regimen of intraperitoneal 
injection of iron, as ferric nitrilotriacetic acid, 
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developed diabetic symptoms of hyperglycemia, glycosuria and 
ketonuria. These rats showed decreased insulin responses to 
oral glucose loading compared to normal controls. 
Histopathology of the iron-treated rats showed marked iron 
deposits in the liver and pancreas though only small amounts 
of iron were detected in the /? cells. When the iron-treated 
rats were phlebotomized, their diabetic symptoms disappeared 
and their pancreases showed no evidence of iron damage and a 
normal number of /5-cell granules was present. These authors 
felt that their results indicated the cause of diabetes in 
hemochromatosis was either a disturbance in iron metabolism 
or iron deposition in pancreatic islet cells. 
While isolated cases of diabetes mellitus in 
thalassemia were known,28'80'81 and Engle25 reported 3 cases 
in 1964, Lassman et. al. in 1974 were the first to 
systematically study and describe a group of patients with 
thalassemia major with documented diabetes mellitus.46'47 
They reported that of 8 patients treated with lifelong 
conventional transfusion therapy, 3 had impaired 
carbohydrate tolerance and 2 had insulin dependent diabetes 
mellitus. They also measured insulin levels during the oral 
glucose tolerance tests and found 30-minute insulin levels 
in the thalassemics to be significantly below their 
controls. The authors concluded that these results were 
consistent with the theory that diabetes mellitus in 




Subsequent series of patients with thalassemia major 
reported similar findings of hyperglycemic, hypoinsulinemic 
responses to oral glucose tolerance tests. In 1976, 
McIntosh studied 9 patients with thalassemia major finding 7 
patients with chemical diabetes mellitus, 4 of which had 
high glucose and low insulin responses to glucose loading.75 
He, too, felt the carbohydrate intolerance was secondary to 
deficient insulin secretion due to pancreatic iron 
deposition. Saudek et. al. in 1977 studied 26 thalassemic 
patients with oral glucose tolerance tests with 13 patients 
displaying abnormal glucose tolerance of which 4 were 
considered "diabetic."76 Zuppinger et. al. in 1979 found 19 
of 22 patients with thalassemia major exhibiting abnormal 
glucose tolerance with affected patients being hyperglycemic 
and hypoinsulinemic during the test.78 Kattamis et. al. 
studied thalassemics younger than 13 years with intravenous 
glucose tolerance tests finding 6 of 27 patients with 
abnormal results and the thalassemics as a group having 
increased glucose and decreased insulin responses to the 
intravenous glucose.82 
In contrast to the above studies, some investigators 
have reported increased rather than reduced insulin 
responses to oral glucose in some hypertransfused patients 
with thalassemia major. Flynn et. al. in 1976 reported the 
results of 40 oral glucose tolerance tests performed on 19 
patients with thalassemia major over a number of years.48 
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They found 5 of 19 patients to have symptomatic diabetes 
mellitus and low insulin levels. However, 3 of the 5 
patients with diabetes mellitus had earlier glucose 
tolerance studies which had showed increased insulin levels 
in the face of only modestly impaired carbohydrate 
tolerance. Finally, some of the 13 patients with normal 
glucose tolerance had increased insulin responses to the 
glucose load. These authors suggested that insulin 
resistance followed by eventual islet-cell failure was a 
possible explanation for the carbohydrate intolerance 
observed in some of the patients. 
Other studies support these findings of 
hyperinsulinemia and proposed an etiology for the insulin 
resistance. In 1977 Costin et. al. reported on 10 
conventionally transfused patients with thalassemia major 
studied before, and for 5 years following, the institution 
of hypertransfusion therapy.49 At the onset of the study, 
only 1 of the 10 patients displayed abnormal glucose 
tolerance on oral glucose tolerance testing. However, after 
4 years of hypertransfusion treatment, half of the 8 
surviving patients had abnormal oral glucose tolerance 
tests. The mean peak insulin levels of the 4 patients with 
normal glucose tolerance were significantly higher than the 
control subjects' as wells as the patients' own pretreatment 
levels. The authors concluded that insulin resistance was 
an important factor explaining the progressive development 
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of carbohydrate intolerance and that increased insulin 
levels were required to maintain normoglycemia. They 
proposed that the etiology of this insulin resistance was 
liver cirrhosis secondary to hemosiderosis. They also, 
however, acknowledged that progressive /3-cell damage was an 
additional factor. Similarly, Dandona et. al. in 1983 
studied 15 transfusion-treated patients (14 with thalassemia 
major and 1 with red blood cell aplasia) who had biopsy- 
proven hemosiderotic hepatic damage.83 Fourteen of the 15 
patients had normal glucose tolerance tests but had 
significantly increased insulin responses during the test 
compared to controls. One patient had overt diabetes 
mellitus. These investigators thought that the 
hyperinsulinemia might represent a compensatory response 
induced by insulin resistance secondary to transfusion- 
acquired hemosiderotic hepatic damage. Interpretation of 
these findings is limited, however, because plasma glucose 
are very variable during oral glucose tolerance testing. 
Furthermore, augmented late insulin secretion due to loss of 
early insulin release, as seen in type II diabetics84-86 
could explain the elevated glucose and insulin levels 
observed in these patients. 
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THE CURRENT INVESTIGATION 
In the present study, the euglycemic insulin clamp, 
hyperglycemic clamp, and oral glucose tolerance test were 
employed to determine whether thalassemia major or its 
treatment with frequent transfusions alters insulin 
sensitivity, insulin secretion, or both before the 
development of diabetes mellitus. The study was designed to 
avoid the problems of bias in regard to age and disease 
state of subjects that were present in previous 
investigations in this field. The findings of the present 
study indicate that increasing iron burden is accompanied by 
impaired insulin sensitivity in thalassemic patients and 
that increasing insulin secretion appears to preserve near 





Patients with thalassemia were drawn from the 
Thalassemia Clinic of the Yale-New Haven Hospital Medical 
Center. The clinic serves patients with thalassemia major 
and thalassemia intermedia. Almost all the patients are of 
Greek or Italian ancestry. Eligibility criteria included: 
age > 8 years; treatment with frequent transfusions (15 ml 
packed erythrocytes per kg body weight every 4-6 weeks to 
maintain a hemoglobin level above 9.0-10.0 g/dl) and 
deferoxamine (1.5-2.0 g per kg per day, up to 6 days per 
week) given by continuous subcutaneous infusion over 8-10 
hours; absence of diabetes87; and the ability to give 
informed consent. Fourteen patients who met these criteria 
were invited and 12 agreed to participate. 
Clinical data are summarized in Table 1. There were 4 
prepubertal (Tanner I) subjects aged 10.2 ±0.5 years (mean 
± standard deviation) and 8 pubertal (Tanner II-V) subjects 
aged 16.0 ± 2.8 years. Three of the pubertal patients 
(numbers 7, 9 and 11) carry the diagnoses of thalassemia 
intermedia. However, they all were requiring similar 
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transfusion and chelation treatments as the 9 thalassemia 
major patients and for purposes of this study were 
considered as patients with thalassemia major. All subjects 
were in good general health, were normally active, were 
taking no medications other than deferoxamine and ascorbic 
acid, and were free of overt cardiac disease. Several had 
mild elevation in serum aspartate aminotransferase (SGOT) 
concentration (Table 1) but serum direct bilirubin levels 
were normal. No patient had detectable antibodies to human 
immunodeficiency virus or hepatitis B virus, unless 
hepatitis B vaccine had been given. Subjects less than 18 
years of age showed no evidence of growth retardation 
(attained heights between the 5-75 percentiles for age) and 
the weight of each patient was within the mean ± 1 standard 
deviation of the expected weight for their height,88 except 
in one modestly overweight subject (patient number 6). All 
had elevated serum ferritin levels (Table 1). Chelation 
therapy was assessed to be good in 10 patients and fair in 2 
(Table 1). Compliance with chelation therapy was estimated 
by frequency of deferoxamine infusions per week: good >5, 
fair 3 or 4, or poor <3 infusions per week. They had 
received between 155-585 units of packed red blood cells 
during their lifetime. Anti-islet cell antibodies were 
assayed in the thalassemic patients (except for 2 
prepubertal patients) in the laboratory of Dr. George 
Eisenbarth (Joslin Research Laboratory, Boston, MA). None 
of the patients had a positive titer. 
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Forty-four healthy children (11 prepubertal and 33 
pubertal) served as age-matched controls (Table 1). All had 
normal fasting glucose and insulin levels, had no recent 
illnesses, and were taking no medications. Preadolescent 
and adolescent control subjects were of similar age, height, 
weight and body surface area as corresponding preadolescent 
and adolescent thalassemic subjects (Table 1). Subjects and 
their parents gave written informed consent before taking 
part in the study and the protocol was approved by the Human 
Investigation Committee of the Yale University School of 
Medicine. 
PROCEDURES 
All subjects were admitted to the Children's Clinical 
Research Center for 3-4 days for performance of euglycemic 
or hyperglycemic clamp studies and glucose tolerance testing 
as well as annual evaluations of cardiac and hematologic 
status. Admissions were timed to coincide with the 
patients' next scheduled blood transfusion which was 
generally given after completion of the studies. 
Developmental staging89 was assessed by a physical 
examination on the day of admission. The subjects remained 




All studies were performed in the morning following a 
10-12 hour overnight fast. Two intravenous catheters were 
inserted prior to the clamp studies: one in an antecubital 
vein for administration of test substances and the other in 
a hand or distal forearm vein of the contralateral arm for 
blood sampling. The blood sampling hand was placed in a 
heated box (60-65 °C) to "arterialize" blood samples.90 
After a rest period of at least 30 minutes, baseline fasting 
blood samples were obtained for measurement of plasma 
glucose and insulin. The euglycemic and hyperglycemic clamp 
techniques have been described in detail elsewhere91 and 
will only be briefly outlined below. 
Euglycemic Insulin Clamp 
The euglycemic insulin clamp procedure was developed in 
order to estimate tissue sensitivity to insulin in vivo. 
With this technique, insulin is administered as a primed 
continuous infusion for 2 hours, in a dose (adjusted for 
height and weight) designed to raise plasma insulin 
concentrations to the same level in all subjects. Because 
the plasma glucose is "clamped" at the same level and the 
increment in insulin is similar in all subjects, the amount 
of glucose required to maintain euglycemia provides an index 
of insulin sensitivity. When insulin is infused in the dose 
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used in the present study (40 milliunits per square meter of 
body surface area per minute), endogenous glucose production 
is usually totally suppressed.92'93 Therefore, the amount 
of infused glucose reflects the amount of glucose being 
metabolized by the tissues of the body. 
For the euglycemic clamp protocol, a prime-continuous 
infusion (40 mU/m2-min) of regular human insulin (Squibb- 
Novo, Princeton, NJ) was administered for 120 minutes. In 
each subject, the plasma glucose concentration was "clamped" 
at approximately 90 mg/dl (5 mmol-1) by simultaneous 
infusion of a 20 percent glucose solution. The glucose 
infusion rate was adjusted to maintain euglycemia on the 
basis of plasma glucose determinations made at the bedside 
every 5 minutes. Blood was also obtained at 20 minute 
intervals for insulin measurements. 
Results in thalassemic patients were compared with data 
from 19 healthy controls: 6 Tanner I, prepubertal subjects 
(age 10.1 ±1.0 year, mean ± standard deviation) and 13 
Tanner II-V, pubertal subjects (age 15.3 ± 3.7 years) who 
were studied under the same conditions. Results in some of 




The hyperglycemic clamp procedure provides a means to 
more precisely quantitate insulin secretion in human 
subjects. With this procedure, exogenous glucose is given 
intravenously to raise plasma glucose levels by the same 
amount in each subject and plasma insulin responses to this 
standardized stimulus are determined. By rapidly raising 
plasma glucose levels toward the hyperglycemic goal within 
20 minutes, the early (first phase) insulin response can be 
quantified accurately and independently.91 
Hyperglycemic clamp studies were performed in the 
Tanner II-V thalassemic subjects during a subsequent visit 
at least 1 month after the euglycemic insulin clamp study. 
With this procedure, the plasma glucose level was acutely 
raised by 125 mg/dl (6.9 mmol/1) above fasting values over a 
5-15 minute period according to a standardized algorithm.91 
Plasma glucose was maintained at this hyperglycemic plateau 
for the remainder of the study (120 minutes) by 
determination of the glucose concentration at 5 minute 
intervals and appropriate adjustment of a variable rate 20% 
glucose infusion. Blood samples were also obtained for 
measurement of plasma insulin and C-peptide at 0, 2, 4, 6, 
8, 10, 20, 40, 60, 80, 100, and 120 minutes. 
Results in these patients were compared with those from 
9 healthy Tanner II-V controls (age 15.7 ± 3.0 years) who 
were studied under the same conditions. 
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Oral Glucose Tolerance Test 
Oral glucose tolerance tests were also performed in the 
morning following an overnight fast, two days before or 
after the euglycemic clamp procedure. Glucose was ingested 
at a dose of 1.75 g per kg body weight to a maximum of 100 g 
and blood samples were obtained at -15, 0, 30, 60, 90 and 
120 minutes for measurement of plasma glucose and insulin. 
Results in the thalassemic subjects were compared to 
those in 5 Tanner I, prepubertal (age 9.7 ± 2.2 years) and 
11 Tanner II-V, pubertal (age 14.8 ± 2.0 years), normal 
subj ects. 
BIOCHEMICAL MEASUREMENTS 
Plasma glucose was measured by the glucose oxidase 
method using a Beckman glucose analyzer (Beckman 
Instruments, Fullerton, CA). Plasma insulin95 and C-peptide 
(Diagnostic Products Corporation, Los Angeles, CA) were 
measured by double antibody radioimmunoassay. Plasma 
ferritin was measured by a solid support radioimmunometric 
assay procedure (Ramco, Inc., Houston, Texas). 
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CALCULATIONS AND ANALYSIS 
Under steady-state conditions of euglycemia during the 
insulin clamp study, the rate of glucose infusion provides 
and index of insulin-stimulated glucose metabolism. This 
rate (expressed as milligrams per square meter of body 
surface area per minute) was calculated during 20-minute 
intervals and adjusted for deviations from the target plasma 
glucose level of 90 mg/dl (5 mmol/1). This "space 
correction" corrects for the addition or removal of glucose 
from the body's glucose space.91 The average glucose 
infusion rate required during the last 60 minutes of each 
clamp study was used for comparison. 
During the hyperglycemic clamp, the rate of glucose 
metabolism (expressed as milligrams per square meter of body 
surface area per minute) was calculated during 20-minute 
intervals and adjusted for deviations from the target plasma 
glucose level of 125 mg/dl above fasting. This adjustment 
is the same "space correction" as calculated for the 
euglycemic clamp. In addition, the hyperglycemic clamp 
results require a correction for urinary glucose loss. The 
plasma insulin and C-peptide responses during the 
hyperglycemic clamp study are biphasic; first (0-10 minutes) 
and second phase (10-120 minutes) responses were calculated 




The General Clinical Research Center CLINFO system was 
used for data collection, collation and analysis. 
Demographic data are presented as means ± standard deviation 
and all other data are expressed as means ± standard error. 
Two group comparisons were made by two-tailed Student's 
unpaired t-tests and comparisons between 3 or more groups by 
analysis of variance. Correlations between variables were 





In prepubertal thalassemic children, the rate of 
glucose infusion required to maintain plasma glucose at 
approximately 90 mg/dl (319 ± 23 mg/m2-min) was similar to 
values in normal prepubertal control children (314 ± 41 
mg/m2 min, p=not significant), Figure 1. As previously 
reported,94 insulin-stimulated glucose metabolism was 
reduced in normal pubertal control subjects (to 224 ± 15 
mg/m2-min, p<0.01 vs. prepubertal controls). However, this 
puberty-associated decline was significantly more pronounced 
in thalassemic subjects to 155 ± 18 mg/m2-min, p<0.01 vs. 
pubertal thalassemics (Figure 1). Among thalassemic 
subjects, responses to insulin were inversely correlated 
with the number of transfusions received (r= -0.77, p<0.01; 
Figure 2), but not with serum ferritin levels (r= -0.26, p= 
not significant; Figure 3). 
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ORAL GLUCOSE TOLERANCE TEST 
Plasma glucose and insulin responses to oral glucose 
are shown in Figures 4 and 5. The glucose and insulin 
responses were within the normal range in prepubertal 
thalassemic subjects. In contrast, carbohydrate tolerance 
was modestly impaired in pubertal thalassemic patients, in 
spite of marked hyperinsulinemia. As shown in Figure 5, the 
area under the insulin response curve was markedly greater 
in pubertal thalassemics than pubertal controls (15.3 ± 1.7 
vs. 6.3 ± 0.6 mU-min/ml, p<0.001 vs. other three groups). 
In thalassemic subjects, the area under the insulin 
response curve was inversely correlated with the rates of 
insulin-stimulated glucose metabolism determined with the 
euglycemic clamp procedure (r=-0.85, p=0.002; Figure 6). 
HYPERGLYCEMIC CLAMP 
First and second phase plasma insulin and C-peptide 
responses to a standard 125 mg/dl (6.9 mmol/1) increment in 
plasma glucose in pubertal thalassemic and pubertal controls 
are compared in Figure 7. Both first and second phase 
insulin responses were markedly higher in pubertal 
thalassemic subjects compared to pubertal controls (phase 
one: 79 ± 14 /xU/ml or 569 ± 101 pmol/1 vs. 26 ± 2 /zU/ml or 
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187 ± 14 pmol/1, p<0.01; phase two: 115 ± 26 ± 2 /iU/ml or 
828 ± 187 pmol.l vs. 47 ± 3 U/ml or 338 ± 22 pmol/1 p<0.01). 
Similarly, the first and second phase rise in circulating 
C-peptide concentrations were significantly greater in 
pubertal thalassemics than in controls (p<0.01, Figure 7). 
Despite higher insulin concentrations in the thalassemics, 
the rate of exogenous glucose infusion required to maintain 
Pi asma glucose at 125 mg/dl (6.9 mmol/1) above fasting was 
not significantly different between the pubertal thalassemic 
subjects (372 ± 46 mg/m2-min ) and the pubertal controls 
(398 ± 57 mg/m2min, p=not significant). 
PATIENTS WITH DIABETES 
Also presented are the results of sequential glucose 
tolerance tests in two female thalassemic patients who were 
excluded from the study because of the presence of diabetes. 
Their glucose intolerance was diagnosed from oral glucose 
tolerance testing. Neither patient had yet begun any 
dietary or pharmacologic therapy at the time of these 
studies. As shown in Figure 8, both patients showed 
enhanced insulin responses to oral glucose in their teenaged 
years when glucose tolerance profiles were observed in 




Diabetes mellitus is a common, late complication in (3- 
thalassemic patients requiring frequent transfusions; a 
problem that has not been totally prevented by use of the 
iron chelating agent deferoxamine.96 Development of 
diabetes in this setting has generally been thought to be 
due to a direct, toxic effect of iron on the pancreatic 
islets leading to insulin deficiency.28•33• 46•47•75• 77”79 
However, a surprising degree of variability in insulin 
responses to oral glucose has been observed in 
hypertransfused thalassemic patients; low, normal and even 
high insulin levels have been 
reported.34,46'48#49,75,7 6,83,97 
Several factors help explain the widely varying insulin 
responses to oral glucose loading that have been observed in 
thalassemic patients. Most studies were cross-sectional 
surveys of entire clinic populations that included patients 
of different ages, sexual maturity and durations of 
treatment which could impact on insulin secretion. These 
studies failed to stratify patients with normal glucose 
tolerance, impaired glucose tolerance and frank diabetes. 
Such differences in carbohydrate tolerance produce marked 
differences in the glycemic stimulus to the (3 cell. 
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Insulin resistance has been suggested as a cause of 
carbohydrate intolerance in thalassemia major.48'49'83 
However, the issue of insulin sensitivity in thalassemia 
major has never been directly studied but only inferred from 
results of oral glucose tolerance tests that showed 
exaggerated insulin responses. The oral glucose tolerance 
test is inadequate for assessing the potential contribution 
of insulin resistance which itself could affect insulin 
secretion in these patients.91 Furthermore, differences in 
insulin responses to oral glucose could be related to time- 
dependent changes in insulin secretion that occur during the 
course of the disease. To circumvent these problems, the 
euglycemic and hyperglycemic clamp techniques were used to 
quantify insulin action and insulin secretion under 
controlled conditions in patients with thalassemia and in 
healthy age-matched control subjects. To focus on early 
changes in carbohydrate metabolism in thalassemia, only 
young subjects without diabetes were included in the study. 
Insulin resistance is defined as a diminished 
biological response to endogenous or exogenous insulin. 
Such decreased response may be due to insufficient or 
ineffective hormone-receptor interactions or defective post¬ 
receptor processing. Either process would result in a 
decrease in the biological response to insulin.98 
Thalassemia and its treatment with multiple 
transfusions could alter carbohydrate metabolism by 
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impairing insulin's action on target tissues. Such insulin 
resistance has been observed in a number of physiological 
and disease states. The most common causes are obesity and 
type II diabetes mellitus. These insulin resistant states 
are often accompanied by hyperinsulinemia with either 
normoglycemia or hyperglycemia. Hyperglycemia itself may 
induce insulin resistance. If overt diabetes mellitus 
develops in such patients, very large doses of insulin are 
often required to attain adequate control. Other causes of 
insulin resistance include acanthosis nigricans, growth 
hormone excess, glucocorticoid excess and lipotrophic 
diabetes.98•99 
Use of the euglycemic and hyperglycemic clamp 
techniques have enabled investigators to examine insulin 
sensitivity in a variety of clinical settings. With these 
methods, decreased insulin sensitivity has been demonstrated 
in types I and II diabetes mellitus in both obese and lean 
patients.92'93'100 Amiel and colleagues at Yale adapted the 
euglycemic insulin clamp technique for studies in 
children.94 With this procedure, they demonstrated that 
puberty is associated with insulin resistance in both normal 
and diabetic adolescents. Furthermore, the decrease in 
insulin-stimulated glucose metabolism seen in puberty was 
not seen in adult subjects who demonstrated the same insulin 
sensitivity as prepubertal subjects. This decline in 
insulin sensitivity in puberty was also demonstrated by 
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Block et. al. in 1987 in a very similar study of healthy 
children using the euglycemic insulin clamp technique.101 
Normal control data generated by the Amiel study also 
provided the opportunity to determine whether insulin 
responsiveness might be altered in hypertransfused 
thalassemia patients. 
The data from the current investigation suggest that 
there is no inherent defect in glucose metabolism in 
thalassemia, since normal insulin secretion, glucose 
tolerance, and peripheral insulin sensitivity were observed 
in prepubertal thalassemic children. These findings are 
consistent with previous studies which failed to find a 
genetic link between thalassemia major and diabetes 
mellitus.46'102>103 Pollack et. al. studied 85 patients 
with thalassemia major and thalassemia intermedia for HLA-A, 
B, C and DR antigens.103 They found no significant 
association between thalassemia and HLA-linked factors known 
to be related to the development of diabetes mellitus. This 
was true for both the group as a whole and the 8 patients 
with clinical diabetes. The absence of anti-islet cell 
antibodies in any of the thalassemic subjects (even in the 
older patients with modestly impaired carbohydrate 
tolerance) is in agreement with a previous study of islet¬ 
cell antibodies in 8 thalassemia major patients aged 15-22 
with chemical or insulin-dependent diabetes104 and along 
with the HLA studies suggests that an underlying autoimmune 
process is unlikely.105-107 
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Nondiabetic pubertal thalassemic patients, on the other 
hand, were found to be markedly insulin resistant, even when 
the normal decline in insulin sensitivity that occurs with 
puberty94'101 is taken into account. During the euglycemic 
clamp studies, insulin-stimulated glucose metabolism was 
reduced by over 30% in the pubertal patients when compared 
with age-matched controls. This impairment in insulin- 
stimulated glucose metabolism was also evident during the 
hyperglycemic clamp procedure. In those studies, total 
glucose disposal was similar in pubertal thalassemics and 
controls, despite 2-3 fold higher circulating insulin 
concentrations in the thalassemics. Insulin resistance was 
correlated with an increased number of transfusions 
suggesting that this acquired defect may have resulted from 
chronic iron overload in muscle and liver tissue. 
In view of the age of the subjects, radioactive tracer 
techniques were unavailable for use to determine whether the 
reduction in insulin action in the pubertal thalassemics was 
occurring at the level of the liver, muscle or both. 
However, tracer studies in normal and insulin resistant 
adult subjects show virtually complete suppression of 
hepatic glucose production during 40 mU/m2min insulin 
infusions.92'93 Therefore, it is reasonable to assume that 
peripheral tissues, rather than the liver, account for the 
insulin resistance that was observed. Increased iron 
content in muscle tissue, as reported in chronic iron 
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overload108 might be particularly important, since muscle 
has been shown to be the principle site of glucose 
utilization under both euglycemic and hyperglycemic 
conditions100'109. The cellular mechanisms leading to this 
resistance, receptor versus post-receptor abnormalities, 
remain to be established. 
Serum ferritin levels did not correlate with the degree 
of insulin resistance in the thalassemia major patients in 
the present study. This finding is somewhat surprising 
since changes in serum ferritin levels have been thought to 
reflect total body iron stores in iron-overloaded 
patients110-112. In studies of multiply-transfused 
patients, the number of lifetime units of blood transfused 
was closely correlated with both serum ferritin and liver 
iron concentration only in patients who had received 50-100 
units of blood.112'113 At higher levels of transfusions the 
increase in ferritin was much less dramatic. Moreover, 
Saudek et. al. reported no correlation between serum 
ferritin levels and patients' ages, transfusion history, or 
degree of glucose tolerance.76 Interestingly, as in the 
current investigation, they noted significantly increased 
age and number of transfusions in the patients with abnormal 
glucose tolerance compared to those with normal glucose 
tolerance. This relationship was most striking in the 
subset of patients with definite diabetes mellitus. 
Inflammation and liver disease113'114 both raise a subject's 
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serum ferritin level. Differences in the measurement 
technique for total ferritin,115'116 also interfere with 
this value's usefulness as a measure of body iron stores. 
Thus, it is possible that transfusion history may be a 
better indicator of total iron burden and degree of 
hemosiderotic damage than serum ferritin. 
Insulin resistance in the pubertal thalassemic patients 
was accompanied by exaggerated increases in plasma insulin 
concentrations during oral glucose tolerance testing, 
particularly early in study. Although this finding could 
represent a compensatory increase in insulin secretion to 
overcome insulin resistance, such a cause and effect 
relationship can not be definitely established with such 
data in as much as plasma glucose levels were higher in the 
thalassemic patients. To evaluate this issue further, 
hyperglycemic clamp studies were performed. This procedure 
provides an identical hyperglycemic stimulus to all subjects 
and allows estimation of both first and second phase insulin 
responses.91'117 It is particularly noteworthy that both 
first and second phase insulin responses were increased the 
pubertal thalassemic subjects. This observation stands in 
contrast to the characteristic loss of first phase insulin 
release that occurs early in the course of type II 
diabetes84-86 and suggests that the evolution of 
carbohydrate intolerance in these two disease processes is 
not strictly comparable. 
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Hyperinsulinemia in patients with thalassemia might 
result from either increased pancreatic insulin release or 
decreased hepatic clearance of insulin, due to liver disease 
caused by iron overload. Insulin is synthesized and 
secreted in the /3 cell as a prohormone consisting of the 
insulin molecule and the C-peptide fragment. When secreted, 
both insulin and C-peptide are released in equimolar 
amounts. C-peptide levels were, therefore, measured during 
the hyperglycemic clamp to provide a more reliable index of 
changes in insulin secretion because hepatic extraction of 
this proinsulin fragment is negligible.118 The observation 
that both first and second phase C-peptide responses were 
enhanced in the pubertal thalassemics supports the view that 
oversecretion of insulin rather than impaired insulin 
degradation was primarily responsible for the 
hyperinsulinemia observed in these patients. This 
conclusion is supported by recent autopsy findings that 
/3-cell mass is increased in iron overloaded patients with 
normal glucose tolerance.119 
On the basis of the findings of this investigation, a 
mechanism may be proposed to explain the changing nature of 
carbohydrate metabolism in thalassemia. In the early stages 
of the disease thalassemic patients show no carbohydrate 
intolerance or altered insulin sensitivity. However, with 
increased iron burden, peripheral sensitivity to insulin 
decreases even in the face of chelation therapy. At this 
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stage, compensatory increases in insulin secretion serve to 
maintain near normal carbohydrate homeostasis, implying that 
impairment of insulin action precedes defects in insulin 
secretion in thalassemia. Ultimately, insulin secretion 
fails to keep pace and overt diabetes develops, as 
illustrated by the glucose tolerance test results in the two 
patients with diabetes. Thus, the appearance of diabetes in 
thalassemic patients may be due to a combination of insulin 
resistance and insulin deficiency; the deficiency due to 
either exhaustion of /9 cells120 or iron deposition in islet 
cells or a combination of these factors. 
Current chelation therapy has not prevented the 
development of carbohydrate intolerance and diabetes 
mellitus in many hypertransfused patients with thalassemia 
major. Further studies are needed to determine the 
biochemical basis for the insulin resistance in thalassemia. 
Such investigation might also provide valuable insight into 
the pathophysiology of insulin resistance seen in other 
conditions such as type II diabetes. Additionally, it will 
be important to determine whether adjunctive therapy with 
sulfonylurea hypoglycemic, that have been shown to increase 
insulin sensitivity,121'122 might delay or prevent the 
development of insulin-dependent diabetes in hypertransfused 




TABLE l: CLINICAL CHARACTERISTICS OF STUDY SUBJECTS 
Patient ** Sex Tanner Age tieiftht Weight Surface Ferritin Hemoglobin Transf usions SGOT 
Stage (years.) (£B1) (k£) Area(m^) (ne. ml) (&M) (total units) (LL_L- 
] M 1 9.7 130 28 1.0 2800 10.0 182 37 
2 F 1 9 8 125 28 1.0 1850 8 9 155 69 
3 M 1 10.6 142 33 1.1 1480 9.8 229 26 
4 M 1 10.7 145 34 1.2 2050 9.2 198 38 
5 F 2 12.4 145 38 1.2 883 9.8 272 26 
6 M 2 13.1 148 52 1.5 4940 10.8 343 57 
7 F 3 13.5 158 58 1.6 3900 8.2 263 122 
8 M 3 14 9 160 64 1.7 3370 12.1 450 130 
9 F 4 17.1 162 55 1.6 3350 9.6 400 88 
10 F 4 18 6 152 54 1.5 1470 8.5 585 74 
11 F 3 19.1 150 47 1.4 2950 9.3 360 39 
12 F 5 19.1 153 54 1.5 2500 10.7 545 47 
Tanner I (mean + SD) !0.2±0.5 136+10 31 + 3 1.1+0 1 
Tanner Il-V (mean + SD) 16.0+2 8 153+6 53+8 1.5+0.2 
Normal Controls 
(mean + SD) 








Tanner 1 1 1 8M/3F 9 9+1.5 137 + 8 30+5 1 1 ±0 1 








Figure Is Rates of insulin-stimulated glucose metabolism 
(upper panel) and steady-state plasma insulin concentrations 
(lower panel) during the euglycemic insulin clamp in 
prepubertal (Tanner I) and pubertal (Tanner II-V) subjects. 
Values (means ± standard error) in prepubertal thalassemics 
(TM) are indicated by the stippled bars, pubertal 
thalassemics by the hatched bars and aged-matched normal 
controls by the open bars. P value refers to the 
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Figure 2: Relationship between insulin-stimulated glucose 
metabolism, as determined by the euglycemic insulin clamp 
procedure, and the number of transfusions received in 
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Figure 3: Relationship between insulin-stimulated glucose 
metabolism, as determined by the euglycemic insulin clamp 








Figure 4: Plasma glucose levels (means ± standard error) 
during oral glucose tolerance testing in pubertal, Tanner 
II-V thalassemics (closed circles) and prepubertal, Tanner I 
thalassemics (open circles). Normal control range of values 














TANNER I TANNER ll-V 
Figure 5: Area under the insulin response curve during oral 
glucose tolerance testing in Tanner I (stippled bars) and 
Tanner II-V (hatched bars) thalassemics (TM) and age-matched 
normal controls (open bars). Asterisk indicates significant 
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Figrare 6: Correlation between the area under the insulin 
response curve and the rate of insulin-stimulated glucose 
metabolism as determined by the euglycemic insulin clamp 






PHASE I PHASE II 
Figure 7: First and second phase plasma insulin (upper 
panel) and C-peptide (lower panel) responses during the 
hyperglycemic clamp study in pubertal thalassemics (TM, 
hatched bars) and pubertal control subjects (open bars). 
Asterisk indicates significant difference vs. corresponding 





Figure 8: Plasma glucose (closed circles) and insulin (open 
circles) levels during sequential oral glucose tolerance 
testing in two female thalassemic patients who have 
developed diabetes. Insulin levels marked with an asterisk 
(Patient B) were reported as >150 /LxU/ml (1080 pmol/1) ; 
actual values may have been greater. Shaded areas in middle 
panels indicate plasma insulin values (means ± standard 
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